laurabbook@gmail.com

Key Takeaways: -Osimertinib significantly improved PFS in unresectable, stage III NSCLC with EGFR mutations post-chemoradiotherapy. -Median PFS was 39.1 months for osimertinib versus 5.6 months for placebo. -Objective response rate and disease control rate were higher with osimertinib. -Safety profile showed higher rates of adverse events in the osimertinib arm,…

*July 2024* In a comprehensive discussion of EGFR-mutant non-small cell lung cancer at the American Society of Clinical Oncology (ASCO) annual meeting, a number of significant advancements were highlighted, particularly from the LAURA trial, which showed improved progression-free survival with osimertinib (Tagrisso) in patients with locally advanced disease. MedPage Today…

*June  2024* Young Lung Cancer Initiative & EGFR Resisters hosted a webinar on June 19th with MD Anderson thoracic surgeon, Mara Antonoff and thoracic oncologist, Carl Gay, to discuss surgery as an option in advanced mutation-driven lung cancer. In case you missed the live event, you can now view the…

*June  2024* GO2 and the EGFR Resisters created this webinar for potential participants to learn about this study. People who have lung cancer or who have had relatives diagnosed with lung cancer hear from the study investigators, Dr. Pasi Janne and Dr. Jaclyn LoPiccolo. They share an overview of the…

*June  2024* In a recent study led by Suresh Ramalingam, MD, executive director of Winship Cancer Institute of Emory University, a new drug has shown remarkable promise in treating patients with a specific type of advanced lung cancer. Osimertinib, produced by AstraZeneca under the brand name Tagrisso, significantly extends the…

*May 2024* Key Takeaways: This combo is a promising treatment for patients with brain mets and/or leptomeningeal disease (LM) after first-line treatment for clinical meaningful rate of time on treatment and radiographic response: Patients with brain mets (PFS=5.9 months; OS=17.9 months) Patients with LM (PFS=8.3 months; OS=14.4 months); RAS/RAF/MAPK pathway…

*May 2024* Question  Among patients with non–small cell lung cancer with the epidermal growth factor receptor (EGFR) variant who experienced resistance to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment, does the addition of ivonescimab (a bispecific antibody targeting programmed cell death 1 protein and vascular endothelial growth factor) to chemotherapy improve progression-free…

*June 2024* This is an excellent presentation at ASCO 2024 by Dr. Jordi Remon Masip on treatment at time of resistance to EGFR TKIs. Those of you wanting to know what the latest is in options after progression on Tagrisso should look at the slide deck of his presentation here.

*June 2024* Purpose Leptomeningeal metastases (LMs) exhibit a high incidence in patients with epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) post-treatment with first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). This investigation evaluates the efficacy, safety, and pharmacokinetics of 80 mg once daily osimertinib in patients with…